According to a recently published report by iData Research (http://www.idataresearch.com), the orthopedic stem cell market was the fastest growing orthopedic biomaterial segment in the US. It aims to provide greater osteoinductive and osteogenesis properties compared to other bone grafts, therefore improving bone repair. These stem cells are currently only being used for spinal procedures, specifically lumbar and cervical indications. But the market may experience further growth as more competitors join the market and as education about stem cell use improves allowing other indications to become approved by the FDA.
“Orthopedic stem cells’ higher average selling price is better tolerated by the commercialized nature of the spine market, explains Dr. Kamran Zamanian, CEO of iData. “As new stem cell products and innovations enter the market, prices should decline, which will aid in greater adoption and in turn fuel the number of procedures using stem cell bone grafts.”
Other key findings from the 2015 iData Research report series entitled U.S. Market for Orthopedic Biomaterials:
Aging Population Use of Stem Cells
With regards to the incidence of osteoarthritis and degenerative joint disease, the aging population is a driver for stem cell therapies, as it is for the orthopedic market in general.
High Cost of Development
Cell-based therapies are generally very costly. Developing a viable stem cell product is currently prohibitively expensive. Definitions and protein markers that help distinguish types of stem cells are often challenging to develop, as these cells change in various clinical settings. The potential reward is appreciable for end-users, but the cost of research and development is a considerable burden for entrants. This will hinder further market growth.
NuVasive led the U.S. orthopedic stem cell market in 2014. They are currently shifting their sales efforts to their second-generation product Osteocel® Plus. NuVasive purchased the Osteocel® line of products from Osiris Orthopedics in 2008. The purchase was to complement their strong spinal hardware business.
Other notable competitors in the orthopedic stem cell market include Orthofix, Biomet, RTI Surgical, and AlloSource.
For Further Information
More on the orthopedic stem cell market in the U.S. can be found in the report published by iData entitled U.S. Market for Orthopedic Biomaterials. This report also covers the U.S. market segments for orthopedic bone graft substitutes, orthopedic growth factors, orthopedic stem cell therapy, orthopedic hyaluronic acid viscosupplementations, orthopedic cartilage repairs, and spinal machined bone allografts.
Full reports also provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about U.S. orthopedic biomaterials market data or procedure data, register online or email us at info(at)idataresearch(dot)net for a U.S. Market for Orthopedic Biomaterials report brochure and synopsis.
About Procedure Tracker
Additional procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by country, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.
About iData Research
iData Research (http://www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.